

COVID-19 CVD Registry Fact Sheet

The American Heart Association® (AHA) has created a Quality Improvement Registry to better understand the clinical treatment patterns and variations, including the collection of biomarkers, and cardiovascular outcomes in hospitalized COVID-

registry. facility with a confirmed diagnosis of COVID-19 by an RT PCR test, either prior to or during the hospitalization, a positive IgM antibody test, or a clinical diagnosis using hospital specific criteria. Please see below for a detailed description of inclusion criteria.

Include



Reporting Measures

Admission to ICU: Percentage of patients with active COVID-19 infection who were admitted or transferred to the ICU.

ACEI/ARB Continued During Hospitalization: Percentage of patients with active COVID-19 infection who received an Angiotensinconverting-enzyme inhibitor (ACEI) or Angiotensin II receptor blocker (ARB) during the hospital admission.

Mechanical Ventilation Required: Percentage of patients with active COVID-19 infection who required mechanical ventilation during admission.

Mean LOS and Medications During Stay: Mean Length of Stay (LOS) for patients with active COVID-19 infection grouped by medications received during admission.

Median LOS and Medications During Stay: Median LOS for patients with active COVID-19 infection grouped by medications received during admission.

Complications: Patients with active COVID-19 infections grouped by complications that occurred during admission.

Stroke or Intracranial Hemorrhage Type: Patients with active COVID-19 infections who had an ischemic stroke or intracranial hemorrhage during admission grouped by type of stroke or hemorrhage.

Type of In-Hospital Shock and Management: Patients with active COVID-19 infections with inhospital shock grouped by type of management.

Evaluation of LV Systolic Function During Admission: Percentage of patients with active COVID-19 infection whose left ventricular (LV) systolic function was evaluated during admission.

Time on Ventilator: Patients with active COVID-19 infection who required mechanical ventilation during admission grouped by time on ventilator.

V-V ECMO during Stay: Percentage of patients with active COVID-19 infection who received veno-venous (V-V) extracorporeal membrane oxygenation (ECMO) for any reason during admission.

Median Time on V-V ECMO: Median time on veno-venous (V-V) extracorporeal membrane oxygenation (ECMO) for patients with active COVID-19 infection and in-hospital shock who were placed on V-V ECMO.

Anticoagulation during L&c (V) ToTc OT5c 9.939 OAD5Tw 9.8939 na Only